BRIEF published on 06/28/2024 at 07:05, 2 years 1 month ago GeNeuro announces the results of the GNC-501 trial in post-Covid-19 syndrome Business Strategy Clinical Test GeNeuro Temelimab Post-Covid-19 Syndrome
PRESS RELEASE published on 06/28/2024 at 07:00, 2 years 1 month ago Inside Information / Other news releases GeNeuro announces results of the GNC-501 study addressing post-COVID-19 neuropsychiatric syndromes. Initial findings show no significant improvement with temelimab treatment compared to placebo GeNeuro Temelimab Neuropsychiatric Post-Covid-19 Syndrome GNC-501 Study
BRIEF published on 06/14/2024 at 18:35, 2 years 1 month ago GeNeuro Announces Unanimous Approval of Resolutions at AGM Shareholders Biopharmaceutical AGM Resolutions GeNeuro
PRESS RELEASE published on 06/14/2024 at 18:30, 2 years 1 month ago Inside Information / Other news releases GeNeuro shareholders approve all resolutions proposed at 2024 AGM, including annual report, re-election of Board members, and compensation approval. 81.54% share capital represented at the meeting Shareholders Compensation AGM Resolutions GeNeuro
BRIEF published on 05/29/2024 at 19:32, 2 years 2 months ago GeNeuro: Information on the General Meeting of June 12, 2024 Shareholders Biopharmaceutical Multiple Sclerosis General Assembly GeNeuro
PRESS RELEASE published on 05/29/2024 at 19:27, 2 years 2 months ago Inside Information / Other news releases GeNeuro announces availability of documents for the annual shareholders’ meeting on June 12, 2024 in Geneva, Switzerland. Documents accessible online and at company headquarters Shareholders' Meeting Annual Meeting GeNeuro Geneva Documents Availability
BRIEF published on 04/30/2024 at 19:59, 2 years 3 months ago GeNeuro presents its 2023 annual results and progresses in its research programs Financial Results Long Covid Medical Research Health GeNeuro SA
PRESS RELEASE published on 04/30/2024 at 19:54, 2 years 3 months ago Inside Information / News release on accounts, results GeNeuro reports 2023 full-year results and provides corporate update including completion of Phase 2 trial for temelimab against post-COVID neuropsychiatric syndromes. Financial visibility extended to Q3 2024 Full-year Results Phase 2 Trial GeNeuro Temelimab Post-COVID
Published on 08/07/2026 at 00:45, 11 hours 16 minutes ago NXT Energy Solutions Announces Second Quarter 2026 Results
Published on 08/06/2026 at 23:15, 12 hours 46 minutes ago LNG Energy Group Announces Issuance of Second Partial Revocation Order and Further Details on Private Placement Financing
Published on 08/06/2026 at 22:15, 13 hours 46 minutes ago Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada
Published on 08/06/2026 at 22:05, 13 hours 56 minutes ago Innodata Reports Record Second Quarter 2026 Results
Published on 08/06/2026 at 22:00, 14 hours 1 minute ago Gold Terra Announces Closing of Second Tranche of the C$10.8M LIFE
Published on 08/07/2026 at 11:12, 49 minutes ago EQS-Adhoc: Asklepios Kliniken GmbH & Co. KGaA submits request for the implementation of a squeeze-out of the minority shareholders of RHÖN-Klinikum Aktiengesellschaft
Published on 08/07/2026 at 11:00, 1 hour 1 minute ago MuniFin Group’s Half Year Report January–June 2026 is published
Published on 08/07/2026 at 11:00, 1 hour 1 minute ago PWO Group generates new business of EUR 363m and increases free cash flow in the first half of 2026
Published on 08/07/2026 at 10:45, 1 hour 16 minutes ago Coolita launches Indonesia's first FAST Media Alliance with leading broadcasters
Published on 08/07/2026 at 08:30, 3 hours 31 minutes ago Disclosure of shares outstanding and voting rights - 07.08.2026
Published on 08/06/2026 at 18:26, 17 hours 35 minutes ago Air Liquide voting rights as of July 31st 2026
Published on 08/06/2026 at 17:45, 18 hours 16 minutes ago Declaration of voting rights at the end of July 2026
Published on 08/06/2026 at 17:35, 18 hours 26 minutes ago Groupe des Assurances du Crédit Mutuel (GACM)’s Solvency II ratio was 227% as of June 30, 2026
